enGene Therapeutics (ENGN) Retained Earnings (2022 - 2026)
enGene Therapeutics (ENGN) posted quarterly Retained Earnings of -$432.0 million for Q2 2026, down 44482.04% year-over-year from N/an in Q2 2025, and down 7.52% quarter-over-quarter from -$401.8 million in Q1 2026.
enGene Therapeutics (ENGN) Retained Earnings (2022 - 2026) Analysis & Trends
enGene Therapeutics (ENGN) has reported Retained Earnings for 5 consecutive years, with -$432.0 million the latest figure, recorded in Q2 2026.
- In Q2 2026, Retained Earnings fell 44482.04% year-over-year to -$432.0 million; the TTM figure through Apr 2026 stood at -$432.0 million (down 44482.04% YoY), while the FY2025 annual figure was -$372.0 million, down 26117.9% from the prior year.
- Retained Earnings retreated to -$432.0 million in Q2 2026 per ENGN's latest filing, from -$401.8 million in the prior quarter.
- Across five years, Retained Earnings topped out at -$969000.0 in Q2 2025 and bottomed at -$432.0 million in Q2 2026.
- Historically, Retained Earnings has averaged -$182.9 million across 5 years, with a median of -$204.9 million in 2023.
- Annual changes were most pronounced in 2025 — Retained Earnings surged 99.39% — and 2026, when it plunged 44482.04%.
- enGene Therapeutics' Retained Earnings stood at -$1.0 million in 2022, then plunged by 19544.49% to -$199.6 million in 2023, then soared by 99.29% to -$1.4 million in 2024, then sank by 26117.9% to -$372.0 million in 2025, then slipped by 16.12% to -$432.0 million in 2026.
- Business Quant data shows ENGN's Retained Earnings at -$432.0 million in Q2 2026, -$401.8 million in Q1 2026, and -$372.0 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.81 Bn | 130.96 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 86.07 Bn | 78.08 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 65.47 Bn | 60.29 Bn | 1.37 Bn | 558.00 Mn |
| 4 | Moderna | 55.64 Bn | 50.50 Bn | 52.00 Mn | 5.10 Bn |
| 5 | BeOne Medicines | 41.99 Bn | 36.89 Bn | 1.53 Bn | 13.05 Bn |
| 6 | Alnylam Pharmaceuticals | 31.68 Bn | 28.37 Bn | 992.69 Mn | -6.33 Bn |
| 7 | BioNTech SE | 27.69 Bn | 9.29 Bn | 668.28 Mn | 20.91 Bn |
| 8 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 6.57 Bn |
| 9 | Royalty Pharma | 27.36 Bn | 26.52 Bn | - | 4.38 Bn |
| 10 | enGene Therapeutics | 123.41 Mn | 123.41 Mn | - | -432.01 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 30, 2026 | -432.00 Mn |
| Jan 31, 2026 | -401.80 Mn |
| Oct 31, 2025 | -372.03 Mn |
| Jul 31, 2025 | -334.15 Mn |
| Apr 30, 2025 | -969,000.00 |
| Jan 31, 2025 | -1.28 Mn |
| Oct 31, 2024 | -1.42 Mn |
| Jul 31, 2024 | -239.43 Mn |
| Apr 30, 2024 | -1.02 Mn |
| Jan 31, 2024 | -210.30 Mn |
| Oct 31, 2023 | -199.59 Mn |
| Oct 31, 2022 | -1.02 Mn |